What Was Approved?
On July 23, 2025, the U.S. Food and Drug Administration approved Anzupgo (delgocitinib) cream for adults with moderate-to-severe chronic hand eczema who have had an inadequate response to topical corticosteroids or for whom topical corticosteroids are not advisable.
How Does Anzupgo Work?
Anzupgo is a topical Janus kinase, or JAK, inhibitor.
It works locally in the skin to reduce inflammatory signaling involved in chronic hand eczema.
How Is Anzupgo Used?
Anzupgo is applied twice daily to affected areas of the hands and wrists.
Patients should follow the exact application instructions in the FDA-approved labeling.
What Did the Clinical Trials Show?
FDA approval was supported by two randomized, vehicle-controlled trials involving about 960 adults with moderate-to-severe chronic hand eczema.
More patients treated with Anzupgo achieved clear or almost clear skin at Week 16 compared with vehicle treatment.
Bottom Line
Anzupgo (delgocitinib) is an FDA-approved topical treatment for certain adults with moderate-to-severe chronic hand eczema when topical corticosteroids are ineffective or not advisable.
Sources
- U.S. Food and Drug Administration (FDA) — Drug Trials Snapshot: Anzupgo.
- U.S. Food and Drug Administration (FDA) — Novel Drug Approvals for 2025.